{"id":889989,"date":"2025-09-26T16:05:20","date_gmt":"2025-09-26T20:05:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/"},"modified":"2025-09-26T16:05:20","modified_gmt":"2025-09-26T20:05:20","slug":"immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/","title":{"rendered":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  26, 2025  (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.<\/p>\n<p>\u201cThese exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has multiple opportunities to engage with and understand these important results,\u201d said Ben Zeskind, Ph.D., CEO of Immuneering.<\/p>\n<p>Individuals interested in listening to the live conference call may do so through this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iGwP_PGUK7ZvxF_cit7LWNaFYYQGIRe_qxKJu4S9zYCmAEYnQACBG7Lw1oHM_FnclbZngC5alTeDfZsBWynz7ypili4m0FG8tRQcqMXHL00cJHbVzPcEjyrok4odlr4DdzIsYdtuMDHGOIz9x35Mp1TYs_Ez7prcBISAPUgQ8o-JfnmZzbTGpMFxefUiT7E04EQg6VWLpc_4ElwlSO1JuR8kOg4ziC1nE7TTGwvnw-zFPnXhMJsrQd1jT9jmj9y2FhcVAbe4VSY0MIFpSca-QnlZVwkHXLgvR69RRI_Kjxyj5k6KLlZPaAD-qPOVokcXv-bTKlh3_90qLq91ZErHPQjxrU_ugb1SNxk9iZ-Q_LoLWs8PYDVTJePiNWPnPM-T_tbBZVKUd2NFHvMBptHeMA==\" rel=\"nofollow\" target=\"_blank\">webcast link<\/a> or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 9502940. A webcast replay will be available from the \u201cInvestors\u201d section of the Company\u2019s website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d-v4sEKtRiWIYfifddo95KSJeQRX5k6UqcFAHJlutxrzALP0iZebIYcqCw9DLZbsfBIQcQMvsX6yirkMOHhLhtFKz6brs_pMDZRaDSmIGRpTsEY3lrFVmoEmrowvMJkpsMQNcKHyKyK7wykXLP0rUMwmpSJKEMMOaItyoN22m8r43U8qe2tviqSAZ9RyqF1ABx86mT5kaFW3GsfWEHTpb3v1XzlJ8zbcpmeXc6wup2kfmNtX1Y2otWlU41sw6rqblmY9Wu2BFlgoF9Azx3btqFhsooeeLtzP3mqQKkakKphwVye1AYSxGVHfdMd1iEeyl1BkcUG3sowNvvO715BkVUjfJxWtosbFQDGnRwxv1C_CXMd9nqt0AlJM15TVjEzEHDEdixxbulNtCwpskWgw1A==\" rel=\"nofollow\" target=\"_blank\">here<\/a>. The Immuneering September 2025 corporate presentation can be found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d-v4sEKtRiWIYfifddo95JEgwr5IZ0H0nLh8x8GAIjvTs_txk85U4QnaEtLZQ9vtRuGLWlTs3UgJGfkIwSI2_0yuGD8jBewb5-xrTCr00DpiLHPtdmDKh-DvU0etnBg6w8G49yh5_uc2U8lgbzO8eBe1ZeGTpogHAIUkL61vbhCGyON1zmF4D4u3CnzgqxziDTAUAYtitd1fwean9HJ6gjkQeMu8ZOnKTswU2vaa9USANPXVKKB2LkMIYDDNU-zrCPB5NHNWJNz_cr2VnfGJIgh2VmfBQ0N_I1smbXrpr7fa9DSUwdvJPMxtZW9phOQbyqtxM0_giytqo9ff45UjX8CC7wI2cccFBPkspwYwPpZ5yWn6eD_6aKGOzVpUH6cakln5LFLdPKiaIot29WQsWl9dnvoqZK3TW4gS7D7-v7fjqNyWFOibdPgL_TCSVnN_\" rel=\"nofollow\" target=\"_blank\">here<\/a> and the September 24, 2025 press release announcing updated overall survival and safety data in first-line pancreatic cancer patients can be found <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d-v4sEKtRiWIYfifddo95GtunluW6Z-ndfB-TK1rK4epcksJ1GtkxawNA_r5LnIN1B75QbLlHn2Bw3BZHFeMrt1X499Z9SL_V7TliMCD7hh0UKIvf8Gc0yzLAthjeIM9b2cUV9iIbAThsH4s9FuY18rsKCnjv20X7d8A9B9AlYDwfeGj-bpEFs69RfycAXWoR-QT0qq8DNNEbTZe6aCT3SG9L_yvzq2hczyO898P2ismsrrL-K7qNNTrJQRWgzO0qhlali-7ivFm2NBQzMsGGZ2E14UlePPlmgulaV2UcPvh-gu-mXXC4NjXrM1QPMCvmAc95htcnt46g_1DkdTi0anEb9kwIU98Q0YIRcgFgqSROpu3MiI_PiuTwTRci_T9nPO5wXJ8Lg-NQbA3y7Y0rKCvk8tFMmmP1vtFFmCBNFEWW4q8-VtNyXFRGWe4WXsunBjM5fdl2JurhHBMLlQHZ7KF-2Fif1Lz-VS9UlrKzovmWKcJVC3TD3H7OCpOcLYx\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Immuneering<\/strong><br \/>\n        <br \/>Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering\u2019s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company\u2019s development pipeline also includes early-stage programs. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yoRcLcZ8-VuRDXZ-JbZ3FF5Cw-deA3jOxmQOuJwQQT3uJVThqR09-z341rkqkRzYg_ooWr2ybd7HnRNw_WJ0PDAeaOtEPZYlbJLQWwMm6QnWmzQLGQGjbio070TpKEgHGhdkuG7SqUlGL88Fbuus5hgIQ2hpBhmoCjczGdAGwJyefDUjKKoHmLzRLuJLzXEPDeNh2KVaTUymT__vq8pDMgss-Jj0e2jsUG-DMsQtcH8CV7ZaSgOFU7iEvQKbcnzICY8uHStsNMPspH6i65vmCXtgrbOsCtrMJ_ENI5P3lCwAmhspSdAI9G3KpzEx8njxBZuy1h1w1DuleytSl63b6BNI-pQ50UmSqOTA4bWHjogtedz74k-n7jQ003Z3pj2i\" rel=\"nofollow\" target=\"_blank\">www.immuneering.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Carson Creehan<br \/>817-412-1096<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AWySUBvd3hNnkY3fIbSdsXebO4LBCvUatan-4st4n_Ur_6G00DhTVQoSTiJR9mMEymD-Yiuz0ftA_-0uEcLY2CUJnCQO1cOtIIGQ_agBlM3OE1fZGeHVlq_1w7-kcy01\" rel=\"nofollow\" target=\"_blank\"><u>carson.creehan@padillaco.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Laurence Watts<br \/>619-916-7620<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VoYR5IsKFd_Uh3CJ7Wopx0fuOO11VHiplShIJ1pD_AYKK3y-0pP1NAef1aZOMzg8tzPRNywu7NNfM9aknujGmIdpItciNsf_m7jR4iMVRx8gPr28G5OFdgpgZa4jRpu2\" rel=\"nofollow\" target=\"_blank\"><u>laurence@newstreetir.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGJjNGRlYmUtZmVkYS00YjRkLWIwNjgtZTBkZjg4OTVhYzRkLTEyMjA5NDktMjAyNS0wOS0yNi1lbg==\/tiny\/Immuneering-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. \u201cThese exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-889989","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. \u201cThese exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has &hellip; Continue reading &quot;Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-26T20:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025\",\"datePublished\":\"2025-09-26T20:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/\",\"name\":\"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\",\"datePublished\":\"2025-09-26T20:05:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/","og_locale":"en_US","og_type":"article","og_title":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk","og_description":"NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. \u201cThese exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has &hellip; Continue reading \"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-26T20:05:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025","datePublished":"2025-09-26T20:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/","name":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=","datePublished":"2025-09-26T20:05:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNjA1NyM3MTY3NjU1IzIyMDkzOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-discuss-recently-announced-overall-survival-data-from-phase-2a-clinical-trial-of-atebimetinib-mgnp-in-first-line-pancreatic-cancer-patients-on-monday-september-29-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/889989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=889989"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/889989\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=889989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=889989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=889989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}